Macrophage activation by endogenous danger signals

被引:436
作者
Zhang, X. [1 ]
Mosser, D. M. [1 ]
机构
[1] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA
关键词
cancer; inflammation; inflammatory bowel disease; macrophages; NF-kappa B; toll-like receptors;
D O I
10.1002/path.2284
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Macrophages are cells that function as a first line of defence against invading microorganisms. One of the hallmarks of macrophages is their ability to become activated in response to exogenous 'danger signals'. Most microbes have molecular patterns (PAMPS) that are recognized by macrophages and trigger this activation response. There are many aspects of the activation response to PAMPS that are recapitulated when macrophages encounter endogenous danger signals. In response to damaged or stressed self, macrophages undergo physiological changes that include the initiation of signal transduction cascades from germline-encoded receptors, resulting in the elaboration of chemokines, cytokines and toxic mediators. This response to endogenous mediators can enhance inflammation, and thereby contribute to autoimmune pathologies. Often the overall inflammatory response is the result of cooperative activation signals from both exogenous and endogenous signals. Macrophage activation plays a critical role, not only in the initiation of the inflammatory response but also in the resolution of this response. The clearance of granulocytes and the elaboration of anti-inflammatory mediators by macrophages; contribute to the dissolution of the inflammatory response. Thus, macrophages are a key player in the initiation, propagation and resolution of inflammation. This review summarizes our understanding of the role of macrophages in inflammation. We pay particular attention to the endogenous danger signals that macrophages may encounter and the responses that these signals induce. The molecular mechanisms responsible for these responses and the diseases that result from inappropriately controlled macrophage activation are also examined. Copyright (C) 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:161 / 178
页数:18
相关论文
共 160 条
[1]   The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO [J].
Abbott, DW ;
Wilkins, A ;
Asara, JM ;
Cantley, LC .
CURRENT BIOLOGY, 2004, 14 (24) :2217-2227
[2]   THE CELL BIOLOGY OF MACROPHAGE ACTIVATION [J].
ADAMS, DO ;
HAMILTON, TA .
ANNUAL REVIEW OF IMMUNOLOGY, 1984, 2 :283-318
[3]   Cutting edge:: Biasing immune responses by directing antigen to macrophage Fcγ receptors [J].
Anderson, CF ;
Mosser, DM .
JOURNAL OF IMMUNOLOGY, 2002, 168 (08) :3697-3701
[4]   Resolvins and protectins in the termination program of acute inflammation [J].
Ariel, Amirarn ;
Serhan, Charles N. .
TRENDS IN IMMUNOLOGY, 2007, 28 (04) :176-183
[5]   Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior [J].
Auffray, Cedric ;
Fogg, Darin ;
Garfa, Meriem ;
Elain, Gaelle ;
Join-Lambert, Olivier ;
Kayal, Samer ;
Sarnacki, Sabine ;
Cumano, Ana ;
Lauvau, Gregoire ;
Geissmann, Frederic .
SCIENCE, 2007, 317 (5838) :666-670
[6]   Fibronectin fragments and their role in inflammatory arthritis [J].
Barilla, ML ;
Carsons, SE .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2000, 29 (04) :252-265
[7]   CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin [J].
Basu, S ;
Binder, RJ ;
Ramalingam, T ;
Srivastava, PK .
IMMUNITY, 2001, 14 (03) :303-313
[8]   Gastroenterology 1 - Inflammatory bowel disease: cause and immunobiology [J].
Baumgart, Daniel C. ;
Carding, Simon R. .
LANCET, 2007, 369 (9573) :1627-1640
[9]   Gastroenterology 2 - Inflammatory bowel disease: clinical aspects and established and evolving therapies [J].
Baumgart, Daniel C. ;
Sandborn, William J. .
LANCET, 2007, 369 (9573) :1641-1657
[10]   Angiogenesis as an immunopharmacologic target in inflammation and cancer [J].
Bian, XW ;
Chen, JH ;
Jiang, XF ;
Bai, JS ;
Wang, QL ;
Zhang, X .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2004, 4 (12) :1537-1547